Michael Makris/LinkedIn
Nov 12, 2025, 04:42
Michael Makris on FDA Approval of GEVV-HEM Gene Therapy for Hemophilia
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”A biotechnology company (GeneVentiv Therapeutics) has received positive FDA feedback to develop their GEVV-HEM gene therapy for hemophilia.
This is AAV based gene therapy with human factor Va as the insert.
I will want a lot of animal data showing lack of thrombogenicity before human trials.”
Read the announcement here.
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning
-
Oct 9, 2026, 14:07Chokri Ben Lamine: Pain After Allogeneic Stem Cell Transplantation in Sickle Cell Disease
-
Oct 9, 2026, 13:55Chandler Purser: AABB 2026 Focuses on Transfusion Safety and Audit-Driven Practice Improvement
-
Oct 9, 2026, 13:48Maxime Dely: Raising Awareness for Blood Donation
-
Oct 9, 2026, 13:48Vera Ghali: Anemia in Myelofibrosis and Its Impact on Treatment Outcomes and Overall Survival
-
Oct 9, 2026, 13:32W David Freeman։ The Mechanical Penumbra in Intracerebral Hemorrhage and Its Potential for Tissue Recovery
-
Oct 9, 2026, 13:11Ayshathul Noora։ Carbetocin vs Oxytocin in Preventing Postpartum Hemorrhage